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Background: Mutations of the p53 oncosuppressor gene are amongst the most frequent aberration seen in
human cancer. Some mutant (mt) p53 proteins are prone to loss of Zn(II) ion that is bound to the wild-type (wt)
core, promoting protein aggregation and therefore unfolding. Misfolded p53 protein conformation impairs
wtp53-DNA binding and transactivation activities, favouring tumor growth and resistance to antitumor therapies.
Screening studies, devoted to identify small molecules that reactivate mtp53, represent therefore an attractive
anti-cancer therapeutic strategy. Here we tested a novel fluorescent curcumin-based Zn(II)-complex (Zn-curc) to
evaluate its effect on mtp53 reactivation in cancer cells.
Methods: P53 protein conformation was examined after Zn-curc treatment by immunoprecipitation and
immunofluorescence assays, using conformation-specific antibodies. The mtp53 reactivation was evaluated by
chromatin-immunoprecipitation (ChIP) and semi-quantitative RT-PCR analyses of wild-type p53 target genes.
The intratumoral Zn-curc localization was evaluated by immunofluorescence analysis of glioblastoma tissues of
an ortothopic mice model.
Results: The Zn-curc complex induced conformational change in p53-R175H and -R273H mutant proteins, two
of the most common p53 mutations. Zn-curc treatment restored wtp53-DNA binding and transactivation
functions and induced apoptotic cell death. In vivo studies showed that the Zn-curc complex reached
glioblastoma tissues of an ortothopic mice model, highlighting its ability to crossed the blood-tumor barrier.
Conclusions: Our results demonstrate that Zn-curc complex may reactivate specific mtp53 proteins and that
may cross the blood-tumor barrier, becoming a promising compound for the development of drugs to halt
tumor growth.
Keywords: Mutant p53, Protein conformation, p53 transcriptional activity, DNA binding, Zinc complex,
Cancer therapy, Glioblastoma, Gene expressionIntroduction
The p53 oncosuppressor is a transcription factor whose
activation in response to DNA damage leads to cell
cycle arrest, senescence, or apoptosis [1]. Approximately
55% of human tumors have genetically identifiable loss
of p53 function mainly by point mutation in the core* Correspondence: gdorazi@unich.it
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reproduction in any medium, provided the or(DNA-binding) domain (DBD) [2], http://p53.iarc.fr. The
DBD (residues 94–312) binds the single Zinc(II) ion and
p53, as many transcription factors, uses zinc to maintain
structure and transactivation function for its wild-type
(wt) activity [3]. Mutant p53 (mtp53) proteins are prone
to loss of Zn(II) ion, which consequently promotes aggre-
gation and therefore protein misfolding [4]. The major con-
sequence of core mutation is loss of sequence-specific
DNA binding to the canonical wtp53-binding site of targettd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cases though, mtp53 proteins may acquire pro-oncogenic
functions contributing to tumor progression [5]; moreover,
loss of the ability of mtp53 to induce the expression of
the E3-ubiquitin ligase MDM2 is thought to be responsible
for the mtp53 enhanced stability [6]. These observations,
and the finding that mtp53 protein is often expressed at
high levels in tumors, make mtp53 reactivation an at-
tractive strategy as anticancer therapy [7]. Many screen-
ing studies are underway to identify small molecules that
reactivate mtp53 by acting on the equilibrium of native
and denatured protein immediately after translation, by
acting on the misfolded states, or by alleviating the mtp53
pro-oncogenic affects (i.e., mutp53/p73 interaction) [5,7,8].
In previous studies we found that ZnCl2 treatment
induced the transition of mutant p53 protein into a func-
tional conformation [9-12]. Although we found that ZnCl2
treatment did not induce cell death by itself, it restored
mt-p53-carrying cell sensitivity to chemotherapy allowing
tumor regression [9-12]. Here we aimed at examine
the effect of a novel Zinc compound, a heteroleptic
pentacoordinated (bpy-9)Zn(curc, Cl) complex (hereafter
indicated as Zn-curc) containing a 4,4’-disubstituted-2,2′-
bipyridine as main ligand and curcumin (curc) and chloride
(Cl) as ancillary ligands [13,14], in mutant p53-carrying
cancer cells. The presence of the curcumin framework in
the Zn-curc complex allows intrinsic fluorescence activity,
therefore we attempted to exploit this feature to evaluate
the intratumoral distribution of Zn-curc in an ortothopic
model of glioblastoma in mice. We choose to use glio-
blastoma because it is the most common and lethal primary
central nervous system (CNS) where inactivation of the p53
gene and the presence of aberrant p53 expression are often
reported [15]. Moreover, glioblastoma presents unique
challenges to therapy due to its location, aggressive
biological behaviour, angiogenesis and diffuse infiltrative
growth. Thus, glioblastoma becomes easily chemoresistant,
besides, the existence of blood-tumor barrier (BTB) repre-
sents an obstacle influencing the therapeutic efficacies
via systemic administration [16].
In this study, we analyzed the biological effect of the
novel Zn-curc complex in several cancer cell lines carrying
different p53 mutations. Immunoprecipitation studies
with conformation-specific antibodies were performed
to evaluate p53 protein conformation after treatment.
Finally, immunofluorescence analysis of glioblastoma tis-
sues, of an ortothopic mice model treated with Zn-curc,
was performed lo look for Zn-curc localization. Our
results show that Zn-curc was effective in reactivating
at least two of the most common p53 mutations, such
as R175H and R273H, and to directly induce apoptotic
cell death. Moreover, Zn-curc localized inside glioblast-
oma tissues suggesting its ability to cross the blood-
tumor barrier.Materials and methods
Ethics statement
All animals were handled in strict accordance with good ani-
mal practice as defined by the relevant national and/or local
animal welfare bodies, and in accordance with the Italian
and European legislation. All work was performed in accord-
ance with the guidelines of the National Cancer Institute
Regina Elena, where there is currently no active Ethical
Committee for animal research, and has been filed with the
Veterinary Service Unit and the Italian Ministry of Health,
in accordance with the Italian and European legislation.
Cell culture and treatments
The human colon cancer RKO (wtp53), glioblastoma
U373MG (expressing R273H p53 mutation) and T98G
(expressing M237I p53 mutation) cell lines were maintained
in RPMI-1640 (Life Technology-Invitrogen), while human
SKBR3 (expressing R175H p53 mutation), MD-MBA231
(expressing p53 mutation R280K) breast cancer cell lines
and human fibroblasts (HF) (kindly provided by S. Soddu,
Regina Elena National Cancer Institute, Rome, Italy) were
maintained in DMEM (Life Technology-Invitrogen), all
supplemented with 10% heat-inactivated fetal bovine serum
plus glutamine and antibiotics.
The following reagents were used: a heteroleptic
pentacoordinated (bpy-9)Zn(curc, Cl) complex containing
a 4,4′-disubstituted-2,2′-bipyridine as main ligand and
curcumin (curc) and chloride (Cl) as ancillary ligands [13]
was dissolved in DMSO and used at the indicated concen-
trations; curcumin was prepared as previously reported
[17]; pifithryn-α (PFT-α) (ENZO Life Sciences, Lausen
Switzerland) was dissolved in DMSO and used at 30 μM;
adryamycin (ADR) was used at 2 μg/ml and ZnCl2 was
used at 100 μM.
Viability and colony assays
Subconfluent cells were plated in triplicate in 60 mm
Petri dishes and 24 h later treated with Zn-curc complex
(20-50-100 μM) for 24 and 48 h. Both floating and ad-
herent cells were collected and cell viability was deter-
mined by Trypan blue exclusion by direct counting with
a haemocytometer, as reported. The percentage of cell
viability, as blue/total cells, was assayed by scoring 200
cells per well three times.
For long-term cell survival, subconfluent cells were
plated in 60 mm Petri dishes and 24 h later treated with
Zn-curc complex (20-50-100 μM). Twenty-four hours later,
plates were washed with PBS and fresh medium was added.
Death-resistant colonies were stained with crystal violet
14 days later.
Cell death/PI staining
Cell death was detected by cytofluorimetric analysis of
propidium iodide (PI)-stained cells staining. Briefly, cells
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with adherent cells recovered from the plates, fixed in
80% ethanol and stained in a PBS solution containing PI
(62.5 mg/mL; Sigma-Aldrich), and RNase A (1.125 mg/mL;
Sigma-Aldrich). Samples were acquired with a FACScan
instrument (Becton Dickinson) and the percentage of cells
in sub-G1 compartment was calculated using ModFit LT
software (Becton Dickinson).
Western blotting and p53 conformational
immunoprecipitation
Total cell extracts were prepared by incubation in lysis
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM
EDTA, 150 mM KCl, 1 mM dithiothreitol, 1% Nonidet
P-40) and a mix of protease inhibitors and resolved by
9-12% SDS-polyacrilamide gel electrophoresis. Proteins
were transferred to a polyvinylidene difluoride membrane
(PVDF, Millipore) and membranes were blocked with 5%
nonfat dry milk in PBS and incubated with the primary
antibodies followed by an anti-immunoglobulin–G-horse-
radish peroxidase antibody (BioRad). Immunoblotting
was performed with the following antibodies: monoclonal
anti-poly(ADP-ribose) polymerase (PARP, BD Pharmingen,
CA, USA), monoclonal anti-p53 (Ab-DO1), polyclonal anti-
p53 (FL393) and polyclonal anti-Bax (all from Santa Cruz
Biotechnology), purified mouse anti-phospho-Histone
H2AX (Ser139) (Millipore, clone JBW301; kindly provided
by S. Soddu, Regina Elena National cancer Institute,
Rome, Italy) and monoclonal anti-β-actin (Calbiochem).
Enzymatic signals were visualized by chemoluminescence
(ECL kit, Amersham Corporation).
P53 protein conformation was evaluated essentially as
described [9]. Briefly, cells were lysed in immunopre-
cipitation buffer (10 mM Tris, pH 7.6; 140 mM NaCl;
0.5% NP40, and protease inhibitors) for 20 min on ice,
and cleared by centrifugation. Pre-cleared supernatants
(200 μg) were immunoprecipitated overnight at 4°C
with the conformation-specific monoclonal antibodies
Pab1620 (wild-type specific) and PAb240 (mutant specific)
(Calbiochem) [18,19] pre-adsorbed to protein G-agarose
(Pierce). Immunocomplexes were collected by centrifuga-
tion, separated by 9% SDS-PAGE and blotted onto PVDF
membrane (Millipore). Immunoblotting was performed
with rabbit polyclonal anti-p53 (FL393).
Immunofluorescence staining
The cells were grown on coverslips and treated with Zn-
curc (100 μM) for 24 h. After treatment, cells were fixed
in 4% formaldehyde for 10 min and then premeabilized
with 0.5% Triton X-100 for 5 min before staining with
conformation antibodies PAb1620 and PAb240 at 1:200
dilution in PBST, overnight at 4°. Cells were then visual-
ized on a Nikon Eclipse Ti-U fluorescence microscope
(Nikon) and the percentage of fluorescent cells wasassayed by scoring 200 cells/field, three times and nor-
malized to Hoechst staining.
RNA extraction and semi-quantitative reverse
transcription (RT)-PCR analysis
Cells and glioblastoma tissues were harvested in TRIzol
Reagent (Invitrogen) and total RNA was isolated following
the manufacturer’s instructions essentially as described
[20]. PCR was performed by using genes specific oligo-
nucleotides under conditions of linear amplification. PCR
products were run on a 2% agarose gel and visualized by
ethidium bromide staining using UV light. The house-
keeping β-actin mRNA was used as internal control.
Chromatin immunoprecipitation (ChIP) assay
Chromatin Immunoprecipitation (ChIP) analysis was car-
ried out essentially as described [21]. Protein complexes
were cross-linked to DNA in living cells by adding for-
maldehyde directly to the cell culture medium at 1% final
concentration. Chromatin extracts containing DNA frag-
ments with an average size of 500 bp were incubated
overnight at 4°C with milk shaking using polyclonal anti-
p53 antibody (FL393, Santa Cruz Biotechnology) and
affinity purified rabbit anti-p73 antibody A300-126A
(lot A300-126A-2, Bethyl Laboratories, Inc). Before use,
protein G (Pierce) was blocked with 1 μg/μL sheared
herring sperm DNA and 1 μg/μL BSA for 3 h at 4°C and
then incubated with chromatin and antibodies for 2 h at 4°C.
PCR was performed with HOT-MASTER Taq (Eppendorf)
using 2 μL of immuniprecipitated DNA and promoter-
specific primers for human p21Waf1, Puma, p53AIP1,
MDM2, MDR1, and cyclin B2 promoters. Immuno-
precipitation with non-specific immunoglobulins (IgG;
Santa Cruz Biotechnology) was performed as negative
controls. The amount of precipitated chromatin measured
in each PCR was normalized with the amount of chroma-
tin present in the input of each immunoprecipitation. PCR
products were run on a 2% agarose gel and visualized by
ethidium bromide staining using UV light.
Immunofluorescence of glioblastoma tissues
Human glioblastoma U373 cells were stably transfected
with a pcDNA3-LUC vector using the cationic polymer
LipofectaminePlus method, according to the manufac-
turer’s instructions (Invitrogen), as previously reported
for in vivo imaging [22]. Mixed population were selected
and luciferase activity was assayed on whole cell extract,
compared to Mock cells (data not shown). Six-week-old
CD-1 athymic nude (nu/nu) mice (Charles River Labora-
tories) were used for in vivo studies. All mouse procedures
were carried out in accordance with Institutional standard
guidelines. 2.5x105 viable U373MG-LUC cells were inocu-
lated into the brain of athymic nude mice and allowed to
develop for about 6 days, as monitored by in vivo imaging
Figure 1 (See legend on next page.)
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Figure 1 Zn-curc impairs survival of mutant p53-carrying cells. (A) Tumor cells (4 x 104) were plated in 60 mm dish and 24 h later treated with
increased amount of Zn-curc (20, 50, 100 μM). Twenty-four hours later, plates were washed with PBS and fresh medium was added. Death-resistant
colonies were stained with crystal violet 14 days later. (B) Death-resistant colonies as in (A) were counted and plotted as percentage ± SD of two
independent experiments performed in duplicate. (C) Cells (3 x 105) were plated at subconfluence in 60 mm dish and the day after treated with
Zn-curc for 24 and 48 h. Cell viability was measured by trypan blue exclusion assay and expressed as percentage ± SD of two independent
experiments. (D) Cytofluorimetric analysis of the SubG1 peak evaluated by Propidium Iodide (PI) staining (upper panel) and microscopical
analysis of SKBR3 cells, mock-treated or treated with Zn-curc (100 μM) for 24 h (lower panel). Percentage of apoptotic cells is shown ± SD of
two independent experiments. (E) SKBR3 and U373 cells were treated with Zn-curc (100 μM) for 24 h. Equal amount of total cell extracts were
subjected to immunoblot with anti-PARP (cleaved form, 87 Kd) or anti-β-actin antibodies. (F) RKO cells were treated with Zn-curc (100 μM),
ZnCl2 (100 μM) or adryamicin (ADR, 2 μg/ml) for 24 h. Equal amount of total cell extracts were subjected to immunoblot with anti-γH2AX
(phopho-Ser139) or anti-β-actin antibodies.
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ciferase activity was quantified by IVIS Imaging System
200 (Caliper Life Sciences, Hopkinton, MA), as previously
reported [22]. Mice were anesthetized with a combination
(i.m., 2 mg/kg) of tiletamine-zolazepam (Telazol, Virbac,
Carros, France) and xylazine (Xilazyne/Rompun, Bayer,
Leverkusen, Germany) given i.m. at 2 mg/Kg. Then mice
were injected i.p. with 150 mg/kg D-luciferin (Caliper Life
Sciences) and imaged 10 to 15 minutes after injection.
Data were acquired and analyzed using Living Image soft-
ware version 3.0 (Caliper Life Sciences). After 6 days, mice
were randomized in two groups (8 mice/group): 1) Mock-
treated or 2) treated with Zn-curc (10 mg zinc/kg body
weight), administrated every day by oral administration,
over the course of one week. Glioblastomas were then
harvested and stored in liquid nitrogen. Frozen tissue
sections were analysed by a Nikon Eclipse Ti-U fluores-
cence microscope (Nikon) and the percentage of fluor-
escent cells was assayed by scoring 200 cells/field, three
times and normalized to Hoechst staining.
Statistics
All experiment unless indicated were performed at least
three times. All experimental results were expressed as the
arithmetic mean and standard deviation (s.d.) of measure-
ments was shown. Student’s t-test was used for statistical
significance of the differences between treatment groups.
Statistical analysis was performed using analysis of variance
at 5% (p < 0.05) or 1% (p < 0.01).
Results
Zn-curc complex induces apoptotic cell death in cancer
cell lines carrying mtp53 (H175 and H273)
To evaluate the biological effect of Zn-curc complex we
performed long-term survival assay in cancer cells lines
carrying different p53 point mutations. Increasing doses
of Zn-curc (20, 50, 100 μM) accordingly inhibited cell
growth of SKBR3 (R175H) and U373 (R273H) cell lines
while did not affect T98G (M237I) and MDA-MB231
(R280K) cell growth (Figure 1A), as evidenced by the
quantification of the colony assays (Figure 1B). In our
hands, Zn-curc did not affect long-term survival of normalhuman fibroblast (HF) (Figure 1A, 1B). Viability assay
show that Zn-curc treatment induced time-dependent
cell death only in SKBR3 and U373 cells compared to T98G
and MDA-MB231 cells that were not affected (Figure 1C).
Moreover, FACS analysis of SKBR3 cells stained with
propidium iodide (PI) showed increased subG1 population
after Zn-curc treatment, highlighting cell death (Figure 1D),
as also evidenced by microscopic analysis (Figure 1D,
lower panel). In agreement, the apoptotic marker PARP
was cleaved in both SKBR3 and U373 cells after zinc
treatment (Figure 1E). Finally, because Zn-curc has
been reported to have DNA intercalating ability [13]
we analysed the potential DNA damage occurring after
treatment. As shown in Figure 1F, Zn-curc induced H2AX
phosphorylation (γH2AX); as positive control of DNA
damage we used the chemotherapeutic agent adryamicin
(ADR) and as negative control we used ZnCl2 treat-
ment. Together, these results suggest that Zn-curc exerted
antiproliferative/apoptotic effects in mtp53-carrying cell
lines, in particular with H175 and H273 mutations.
Zinc-curc reactivates p53-DNA binding and
transactivation activities
To determine if the cell death and DNA damage induced
by Zn-curc were correlated to reactivation of wild-type
p53 activity, we performed chromatin immunoprecipita-
tion (ChIP) analyses. The results revealed the ability of
Zn-curc to restore p53-DNA binding activity to wild-type
target gene promoters, including p21, PUMA, p53AIP1,
and MDM2, to the detriment of mtp53-activated pro-
moters, such as MDR1 and cyclin B1 [23,24] (Figure 2A).
We also performed ChIP analyses using the p73 antibody
because one of the mtp53 oncogenic characteristics is
binding of the family member p73 with inactivation of
p73 pro-apoptotic function [24,25]. Parallel to p53 results,
ChIP analyses revealed that the p73 recruitment onto
target promoters was induced after Zn-curc treatment,
mirroring that of reactivated mt/wtp53 (Figure 2A). These
results corroborate the findings that mtp53 can control
molecules such as cyclin B1 and p73 that regulate, re-
spectively, cell cycle progression and apoptosis, supporting
its pro-tumorigenic effect.
Figure 2 (See legend on next page.)
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Figure 2 Zn-curc restores wild-type p53-DNA binding and transactivating activities. (A) SKBR3 and U373 cells (6x106) were plated in 150 mm
dish and the day after treated with Zn-curc (100 μM) for 16 h before assayed for chromatin immunoprecipitation analysis (ChIP) with anti-p53
or anti-p73 antibodies. PCR analyses were performed on the immunoprecipitated DNA samples using primers specific for wtp53 target gene
promoters (p21, Puma, p53AIP1, MDM2) or for mtp53 target promoters (MDR1, cyclin B2). A sample representing linear amplification of the total
chromatin (Input) was included as control. Additional controls included immunoprecipitation performed with non-specific immunogloblulins (No Ab).
(B) Cells (3x105) were plated at subconfluence in 60 mm dish and the day after treated with Zn-curc for 24/48 h. p53 target genes were detected by
RT-PCR analysis. Gene expression was measured by densitometry and plotted as fold of mRNA expression over control (Mock), normalized to β-actin
levels, ±SD. (C) SKBR3 and U373 cells were plated at subconfluence in 60 mm dish and the day after treated with Zn-curc (100 μM) for 24 h, with or
without p53 inhibitor pifithrin-α (PFT-α) (30 μM). p53 target genes were dtected by RT-PCR analysis. β-actin was used as control. (D) Gene expression as
in (C), was measured by densitometry and plotted as fold of mRNA expression over control (Mock), normalized to β-actin levels, ±SD. (E) SKBR3 and
U373 cells were treated with Zn-curc (100 μM) for the indicated hours and total cell extracts were subjected to immunoblot analysis. (F) U373 cells
were plated at subconfluence in 60 mm dish and the day after treated with curcumin (Curc) (50, 100 μM) for 24 h. Zn-curc (100 μM for 24 h) was used
as control of p53 activation. p53 target genes were detected by RT-PCR. β-actin was used as control.
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genes (i.e., Bax, Noxa, Puma, p21) and found that
Zn-curc increased the levels of all four p53 target genes
analysed in U373 cells, particularly the apoptotic ones,
while did not induce p53 target genes in T98G and
MD-MB231 cells (Figure 2B). The specific effect of
Zn-curc in reactivating p53 transactivation function was
evaluated by using the p53 inhibitor pifithrin-α (PFT-α)
[26] that indeed impaired the increase of wtp53 target
genes in SKBR3 and U373 cells after Zn-curc treatment
(Figure 2C), as confirmed by densitometric analyses
(Figure 2D). Finally, immune-blot experiments show that
Zn-curc treatment enhanced Bax protein levels in both
SKBR3 and U373 cells (Figure 2E). These results support
the findings that Zn-curc treatment was indeed restoring
wtp53 transcriptional activity. As Zn-cur complex previ-
ously showed increased biological activity compared to
curcumin alone [13,14], here we tested the effect of
curcumin (curc) on p53 reactivation. We found that
curcumin alone did not induce wtp53 target gene tran-
scription (Figure 2F), suggesting that the effect of
Zn-curc on mtp53 reactivation was mainly depended on
Zn(II) ability to induce mtp53 reactivation.
Zinc-curc induces conformational changes in p53-R175H
and –R273H mutant proteins
Because Zn-curc reactivated p53 transactivation function,
we next analysed mtp53 protein conformation. Using im-
munofluorescence analyses we found that Zn-curc induced
a conformation change in the R175H and R273H mutant
p53 proteins that was recognized by the wild-type-specific
antibody PAb1620 to detriment of the mutant-specific con-
formation detected by the antibody PAb240 (Figure 3A).
Quantification of the fluorescence positive cells showed a
strong reduction of PAb240 intensity whereas PAb1620 in-
tensity was highly increased following Zn-curc treatment
(Figure 3B). The RKO cell line, carrying wild-type p53 was
used as a control to show that the wtp53 conformation was
not changed by Zn-curc treatment (Figure 3A), as also
shown by quantification analyses of fluorescent positivecells (Figure 3C). Immunoprecipitation analysis revealed
that the p53 immunoreactivity to the PAb240 antibody re-
markably reduced after Zn-curc treatment (Figure 3D).
Altogether, these results demonstrate that Zn-curc modi-
fied the equilibrium between p53 mutant and wild-type
conformation toward wild-type conformation.
Zinc-curc localizes in glioblastoma tissues of an
orthotopic mice model
Targeting a tumor tissue with a systemically administrated
anticancer drug is of great importance especially for those
tumors difficult to reach such as brain tumor where the
blood-tumor barrier (BTB) plays a negative role. Therefore,
we took advantage of the fluorescent feature of the Zn-curc
compound [13,14] to evaluate its intratumoral localization.
To this aim we used human U373 glioblastoma cells
engineered with luciferase reporter (U373-LUC) for
imaging analysis [22]. U373-LUC cells were injected into
the brain of athymic nude mice. Ortothopic tumors were
let to growth for 6 days, as evaluated by imaging analysis
(data not shown), before treating animals with Zn-curc
(10 mg/Kg) every day for 7 days. Glioblastoma untreated or
treated tissues were then harvested and analysed with a
fluorescent microscope that revealed a diffuse fluorescence
into the glioblastoma tissues treated with Zn-curc, com-
pared to the Mock-treated tumors (Figure 4A), as also
evidenced by quantification of the fluorescence positive
cells (Figure 4B). In addition, RT-PCR analyses of the
U373-derived tumors showed reactivation of the wtp53 tar-
get genes (Puma and Noxa) only after Zn-curc treatment to
detriment of mutant p53 target gene MDR1 (Figure 4C);
moreover, VEGF and Bcl2 mRNA levels were markedly
downregulated in the Zn-curc-treated tumors (Figure 4C).
These findings indicate that Zn-curc complex can reach the
intratumoral localization and modify molecular pathways
for antitumor purpose.
Discussion
Mtp53 proteins may drive tumor progression, metastasis
and resistance to therapies [8]. In the clinic, the functional
Figure 3 Zn-curc induces a wild-type-like conformational change in mutant p53 proteins. (A) Immunofluorescence of SKBR3 (H175) and
U373 (H273) cells using p53-conformation-specific antibodies (PAB1620 for wt, folded conformation and PAB240 for mutant, unfolded
conformation). Cells were treated with Zn-curc (100 μM) for 24 h before fixing and staining with antibodies. The RKO (wtp53) cell line is used as a
control to show that the wtp53 conformation is not changed by Zn-curc treatment. Quantification of SKBR3 (B) or RKO (C) positive cells to
PAB1620 and PAB240 antibodies before and after Zn-curc treatment, ±SD. (D) SKBR3 and U373 cells were treated with Zn-curc (100 μM) for 24 h.
Total cell extracts were imunoprecipitated (IP) with conformation-specific antibodies (PAB1620 and PAB240) and then imunoblotted (WB) with
anti-p53 (DO1) antibody. Input represents 1/10 of total cell extracts used for IP.
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gression, and therapeutic response of tumors [27]. As a
matter of fact, abrogation of mtp53 expression reduces
tumor malignancy [28] and tumors containing wild-type
p53 are usually more sensitive to radiotherapy or chemo-
therapy than those bearing mtp53 [29]. Moreover, earlier
studies showed that the reconstitution of p53 has different
biologic effects in tumor cells and in nontransformed cells
[30,31]. Therefore, p53 reactivation is a promising antican-
cer strategy [32].
In the last years, many several small molecules have been
claimed to reactivate mutant p53 by acting on the equilib-
rium of native and denatured protein, on the misfolded
states, or by alleviating the mtp53 pro-oncogenic affects(i.e., mtp53/p73 interaction) [5,8]. We previously reported
that the natural molecule ZnCl2 reverts p53 misfolding,
thereby abrogating mtp53 pro-oncogenic function and
increasing the response of mutant p53 tumor cells to
anticancer drugs [9-12]. Zinc is a component of more
than 3000 zinc-associated transcription factors, including
DNA-binding proteins such as p53 [33]. Interestingly, p53
mutations are prone to loss of Zn(II) ion, which as a result
promotes aggregation and therefore protein misfolding
[4]. Many tumor-associated p53 mutations, classified as
contact (e.g., R273H and R273C) or structural mutations
(e.g., R175H, V143A, Y220C, G245S, R249S, F270L, R282W),
may change the DBD conformation resulting in dimin-
ished DNA binding activity [34]. Zinc stabilizes the p53
Figure 4 Zn-curc reactivates mtp53 in an orthotopic U373 glioblastoma model. (A) U373MG-LUC cells (2.5x105) were injected into the brain
of athymic mice and left to growth for 6 days before treating animals with Zn-curc every day for 7 days. Mock- or Zn-curc-treated U373M-derived
tumors were then harvested and analysed with a fluorescent microscope that showed as diffuse fluorescence only in Zn-curc-treated tumors.
(B) Quantification of tumor cell fluorescence positivity in U373-derived tumors, untreated or Zn-curc-treated, ±SD. (C) Total mRNA was
extracted from harvested U373-derived tumors, untreated or Zn-curc-treated, and p53 target gene expression as well as VEGF, MDR1 and Bcl2
expression were assayed by PCR of reverse-transcribed cDNA. Gene expression was measured by densitometry and plotted as fold of mRNA
expression over control (Mock), normalized to β-actin levels, ±SD.
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why in our hands ZnCl2 may influence specifically only
R175H and R273H mutant proteins needs in-depth
analysis.
The beneficial effects of ZnCl2 treatment as antitumor
agent were shown in pivotal studies where zinc alone
was reported to reduce tumor growth and aggressiveness
with limited biotoxicity for instance in prostate cancer
[35]. Very few studies, however, report the use of zinc in
combination with chemotherapy, in fact as far as we
know, zinc is not administered as part of any modern
chemotherapy program in the treatment of cancer. Our
previous pre-clinical studies performed in xenograft tumors
show that ZnCl2 improves the chemotherapeutic effect
reducing tumor growth compared to drug treatment alone
[21]. This outcome could be reached because the ZnCl2
ability to target intratumoral hypoxia and restore p53
activity [21,22,36]. Moreover, in vivo studies in a mice
tumor model with the transgenic MMTV-neu spontaneous
breast cancer that develops p53 misfolding corroborated
the findings that ZnCl2 reactivates misfolded p53 proteins
and enhances antitumor effects of chemotherapy [12].
Interestingly, we recently demonstrated that zinc supple-
mentation is required for the drug-induced immunogenic
cell death in chemoresistant p53-functionally defective can-
cer cells [37] centering the 2 ideal goals of anticancer ther-
apy that are the induction of a strong cytotoxic response of
tumor cells [38] and the stimulation of host tumor-specific
response, cooperating in the achievement of clinically rele-
vant effects [39]. Altogether, these findings emphasize the
translational potential of zinc in clinical practice.
Here we attempted to evaluate the effect of a novel
Zinc(II) compound containing a 4,4′-disubstituted-2,2′-
bipyridine as main ligand and curcumin and chloride as
ancillary ligands [13,14]. As for ZnCl2, Zn-curc modifiedthe equilibrium between p53 mutant and wild-type con-
formation toward wild-type conformation, specifically
affecting R175H and R273H mutant proteins. Differently
from ZnCl2 of our previous studies though [9-12], Zn-
curc was able to directly induce apoptotic cell death likely
due to p53 reactivation following both conformational
changes and DNA damage induction, as evidenced by
phosphorylation of histone γH2AX. Thus, Zn-curc metal
complex combines DNA intercalating ability and cytotoxic
activity with fluorescence [13,14]. This latter characteristic
was in addition particularly useful in testing the capacity
of Zn-curc to reach the tumor site in vivo. To this pur-
pose, we used the ortothopic mice model of glioblastoma
whose treatment remains a challenge due to its location,
aggressive biological behaviour, angiogenesis and diffuse
infiltrative growth, other than to the existence of blood-
tumor barrier (BTB) representing an obstacle to the
therapeutic efficacy via systemic administration [16,40].
Zn-curc was detected in the glioblastoma tissues, highlight-
ing its capacity to reach the tumor site and affect molecular
pathways important for tumor angiogenesis, and impair-
ment of response to therapies such as VEGF, MDR1 and
Bcl2. Targeting of such pathways might be important for
restoring the response to anticancer therapies [41].
In summary, in this study we described the antitumor
effect of a novel compound which combines the Zn(II)
ability to reactivate some tumor specific p53 mutations
with cytotoxic activity (due to its DNA intercalating ability)
and fluorescence feature (due to the curcumin moiety).
This Zn-curc complex might be useful in developing effi-
cient anticancer drugs becuase (i) its ability to target one of
the most common p53 mis-sense mutant, that is R1775H
(http://www-p53.iarc.fr), (ii) its cytotoxic effect specific for
tumor cells, and (iii) its capacity to cross the BTB when
systematically administered.
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